Palisade Bio shows promising Phase 1a/b data for once-daily ulcerative colitis drug PALI-2108.

Palisade Bio announced new Phase 1a/b data for PALI-2108, an oral PDE4 inhibitor designed for targeted delivery to the colon and ileum in ulcerative colitis patients. The data show sustained active metabolite levels above the IC90 threshold, supporting once-daily dosing and localized drug activity in the colon, which reduces inflammation and fibrosis pathways. Clinical improvements were observed in biomarkers and histology, with 100% clinical response and 40% remission in patients. These results support advancing PALI-2108 into Phase 2 trials for ulcerative colitis and Crohn's disease.